Survey on Anemia Therapy in Patients With Chronic Kidney Disease Not on Dialysis

Kidney Disease, Chronic Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02238067
• Other study ID #: ML25473
• Status: Completed
• Phase: N/A
• First received: September 10, 2014
• Last updated: August 1, 2016
• Start date: September 2011
• Est. completion date: August 2013

Study information

• Verified date: August 2016
• Source: Hoffmann-La Roche
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel:Ethics Committee
• Study type: Observational

Clinical Trial Summary

This study is a prospective, non-interventional, cross-sectional multicenter survey. The aim is to better understand the current therapy pattern for anemia in chronic kidney disease (CKD) treated with erythropoiesis-stimulating agents (ESAs) and not on-dialysis patient population in Israel. Participating physicians will be requested to complete a satisfaction survey for anemia treatment for eligible patients with CKD not on dialysis. The survey will be completed twice, once at study start and once at six months' follow-up.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 196
• Est. completion date: August 2013
• Est. primary completion date: August 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients with CKD stage 3-5

• Treated with ESAs

• Written informed consent

• Patient is speaking the same language as the investigator interviewer

Exclusion Criteria:

• Past or current treatment with dialysis

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Chronic Disease
• Kidney Disease, Chronic
• Kidney Diseases
• Renal Insufficiency, Chronic

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Hoffmann-La Roche

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients according to the different ESAs, frequency of use		Until study completion, maximum period of 2 years	No
Secondary	Patients' preference for treatment frequency as assessed by physician via a satisfaction survey		At study start and at 6 months follow-up	No
Secondary	Patients' preference for treatment administration methods, by physician via a satisfaction survey		At study start and at 6 months follow-up	No